EMEA-000170-PIP02-10-M02

Key facts

Invented name
Revolade
Active substance
Eltrombopag
Therapeutic area
Gastroentology-Hepatology
Decision number
P/0007/2015
PIP number
EMEA-000170-PIP02-10-M02
Pharmaceutical form(s)
  • Powder for oral suspension
  • Film-coated tablet
Condition(s) / indication(s)
Treatment of secondary thrombocytopenia
Route(s) of administration
Oral use
Contact for public enquiries
GlaxoSmithKline Trading Services Limited
Ireland
E-mail: eu-paediatric-plans@gsk.com
Tel. +44 (0)20 8990 3650
Fax +44 (0)20 8990 3511
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating